UNSPSC 51131662: Parnaparin

This classification denotes a low molecular weight heparin with the molecular formula (C14H18NO11)n.2(C12H16NO13S)n.3HO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M316WT19D8, chemically known as (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate, but generally known as Parnaparin. European Medicines Agency schedules Parnaparin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22270.

The term Parnaparin is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). As of Q4 2014, PARNAPARIN remains the US FDA Preferred Term for this commodity. SMILES: C(C1C(C(C(C(O1)O)NS(=O)(=O)[O-])O)OC2C(C(C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-].

UNSPSC 51131662 Parnaparin is a Commodity code with no recent state and local procurement activity directly aligned to this specific pharmaceutical product. The single recent opportunity tagged to this code—Sourcewell RFP #061626 for Law Enforcement Equipment—does not procure parnaparin or any pharmaceutical goods; the mismatch suggests a classification error in the source notice rather than an active market under this code. State and local health departments, emergency medical services agencies, correctional facilities, and other public-sector healthcare operations would be the expected issuing bodies for anticoagulant pharmaceuticals like parnaparin, but the available record shows no such solicitations.

Without recent verified opportunities, no geographic concentration or representative recent procurement activity can be established for this code. Business development professionals should verify whether parnaparin procurement activity exists under alternative UNSPSC codes, or direct outreach to state purchasing offices, correctional departments, and public-health agencies to identify whether demand for this anticoagulant is being solicited through cooperative purchasing agreements, state pharmaceutical contracts, or direct agency buys outside visible public notice channels.